• Quick Order
  • Careers
  • Support
Iridescent purple sphere of the influenza virus with protruding knobby spikes

The Importance of Authenticated Viral Standards in Respiratory Disease Research and Therapeutic Development

October 11, 2018, at 12:00 PM ET


Throughout the world, acute respiratory infections are responsible for millions of deaths annually and are a leading cause of mortality in children. Even if not fatal, these infections can be debilitating and often result in hospitalization. Viruses such as influenza virus, respiratory syncytial virus, and enterovirus are major contributors to this disease burden. Emerging viruses have also posed significant risks to human health, as demonstrated by the SARS coronavirus outbreak in 2003 and the recent emergence of the MERS coronavirus. This underscores the importance of effective respiratory virus diagnostic assays, vaccines, and antiviral therapies. In this presentation, we will summarize the impact of respiratory viral disease on global health initiatives; the latest efforts to control and prevent infections (e.g., the universal influenza vaccine); and the importance of authenticated viruses and derivatives in the development of diagnostic assays, vaccines, and antiviral therapeutics.

Key Points

  • Endemic and emerging respiratory virus infections represent a significant global heath burden.
  • Understanding respiratory virus epidemiology and pathogenesis is critical for the development of antiviral therapies.
  • Authenticated viral standards and derivatives are essential tools for the development and validation of novel preventative and therapeutic techniques.

Watch The Presentation


Reed Shabman, headshot.

Reed Shabman, PhD

Lead Scientist, ATCC Standards Resource Center

Reed Shabman, Ph.D., is a Lead Scientist with over 12 years of research experience in the fields of cell biology, immunology, virology, and molecular biology. He has extensive familiarity with research conducted in biocontainment facilities and advanced knowledge of planning and executing biodefense studies. At ATCC, he works in a team that provides custom cell and microbial services to both private and public entities. Before joining ATCC, Dr. Shabman received his doctoral training at the University of North Carolina at Chapel Hill and performed postdoctoral work at the Icahn School of Medicine at Mount Sinai in New York.